Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation

Ophthalmic Genetics

Volumn 30, Issue 3, 2009, Pages 121-126

  Dimaras, Helen ^a   Hon, Elise ^a   Budning, Andrew ^a   Doyle, John J ^a   Halliday, William ^a   Gallie, Brenda L ^a   Chan, Helen S L ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cerebrospinal fluid metastasis; Childhood cancer chemotherapy; Multidrug resistance; P glycoprotein; Retinoblastoma

Indexed keywords

ACETAZOLAMIDE; CARBOPLATIN; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; TOPOTECAN; VINCRISTINE;

ARTICLE; ASTROCYTOSIS; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID METASTASIS; CLOSED ANGLE GLAUCOMA; COMPUTER ASSISTED TOMOGRAPHY; CORNEA EDEMA; ECHOOCULOGRAPHY; ENUCLEATION; EXOPHTHALMOS; HUMAN; INFANT; INTRAOCULAR PRESSURE ABNORMALITY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DETACHMENT; RETINOBLASTOMA; TREATMENT RESPONSE; TUMOR REGRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBROSPINAL FLUID; COMBINED MODALITY THERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; EYE ENUCLEATION; HUMANS; INFANT; MALE; PROGNOSIS; RETINAL NEOPLASMS; RETINOBLASTOMA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 70350676961     PISSN: 13816810     EISSN: 17445094     Source Type: Journal    
DOI: 10.1080/13816810902988780     Document Type: Article

References (23)

1. Gallie BL, Zhao J, Vandezande K, White A, Chan HS. Global issues and opportunities for optimized retinoblastoma care. Pediatr Blood Cancer. Dec 2007;49(7 Suppl):1083-1090.
2. Chan HS, Thorner PS, Haddad G, Gallie BL. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology. Sep 1991;98(9):1425-1431.
3. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L,Mol CA, van derValkMA, Robanus-Maandag EC, te Riele HP, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. May 20 1994;77(4):491-502.
4. Murphree A. Intraocular retinoblastoma: the case for a new group classification. In: Singh A, ed. Ophthalmic Oncology, Ophthalmology Clinics of North America. Vol 18. Philadelphia: Elsevier Saunders; 2005:41-53.
5. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol. Mar-Apr 1963;67:164-172.
6. Greenfield JP, Schwartz TH. Catheter placement for Ommaya reservoirs with frameless surgical navigation: technical note. Stereotact Funct Neurosurg. 2008;86(2):101-105.
7. Common Terminology Criteria for Adverse Events.
8. Klein JL, Hamm C, Dansey RD, Karanes C, Abella E, Cassells L, Peters WP, Baynes RD. High-dose chemotherapy and CD34- selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow. Bone Marrow Transplant. Dec 2001;28(11):1023-1029. (Pubitemid 34030648)
9. Gunduz K, MuftuogluO,Gunalp I, Unal E, Tacyildiz N. Metastatic retinoblastoma clinical features, treatment, and prognosis. Ophthalmology. Sep 2006;113(9):1558-1566.
10. Dunkel IJ, Aledo A, Kernan NA, Kushner B, Bayer L, Gollamudi SV, Finlay JL, Abramson DH. Successful treatment of metastatic retinoblastoma. Cancer Nov 15 2000;89(10):2117-2121.
11. Rodriguez-Galindo C, Wilson MW, Haik BG, Lipson MJ, Cain A, Merchant TE, Kaste S, Pratt CB. Treatment of metastatic retinoblastoma. Ophthalmology. Jun 2003;110(6):1237-1240.
12. Kremens B,Wieland R, Reinhard H, Neubert D, Beck JD, Klingebiel T, Bornfeld N, Havers W. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant. Feb 2003;31(4):281-284.
13. Namouni F, Doz F, Tanguy ML, Quintana E, Michon J, Pacquement H, Bouffet E, Gentet JC, Plantaz D, Lutz P, Vannier JP, Validire P, Neuenschwander S, Desjardins L, Zucker JM. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer Dec 1997;33(14):2368-2375.
14. Sandri A, Besenzon L, Acquaviva A, Marino C, Cordero di Montezemolo L, Madon E. "Eight drugs in one day" chemotherapy in a nonfamilial bilateral retinoblastoma with recurrent cerebrospinal fluid metastases. Pediatr Hematol Oncol. Nov-Dec 1998;15(6):557-561.
15. Duffher PK. Long-term effects of radiation therapy on cognitive and endocrine function in childrenwith leukemia and brain tumors. Neurologist. Nov 2004;10(6):293-310.
16. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, Seddon J, Tarbell N, Boice JD, Jr. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. Jul 21 1993;85(14):1121-1128.
17. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol. Sep 1993;11(9):1629-1635.
18. ScanlonKJ, Funato T, Pezeshki B, Tone T, Sowers LC. Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells. Cancer Commun. 1990;2(10):339-343.
19. Slater LM, Cho J, Wetzel M. Cyclosporin A potentiation of VP- 16: production of long-term survival in murine acute lymphatic leukemia. Cancer Chemother Pharmacol. 1992;31(1):53-56.
20. Chan H, Gallie B, Munier F, Popovic M. Chemotherapy for retinoblastoma. In: Singh A, ed. Ophthalmic Oncology, Ophthalmology Clinics of North America. Vol 18. Philadelphia: Elsevier Saunders; 2005:55-63.
21. Takimoto CH, Arbuck SG. Clinical status and optimal use of topotecan. Oncology (Williston Park). Nov 1997;11(11):1635- 1646; discussion 1649-1651, 1655-11637
22. Chan HS, CantonMD, Gallie BL. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res. Mar-Apr 1989;9(2):469-474.
23. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. Jan 1 2003;21(1):143-147.